{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:20Z","timestamp":1792525580738,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["1010 PY (2023)-30"],"award-info":[{"award-number":["1010 PY (2023)-30"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dld.2026.10.007","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:34:19Z","timestamp":1792438459000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative risk of incident Clostridioides difficile infection with vedolizumab versus anti\u2011TNF in ulcerative colitis: A retrospective cohort study"],"prefix":"10.1016","author":[{"given":"Jiahui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-1226","authenticated-orcid":false,"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.10.007_bib0001","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","article-title":"Higher incidence of clostridium difficile infection among individuals with inflammatory bowel disease","volume":"153","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.10.007_bib0002","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0003","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MCG.0000000000000968","article-title":"The impact of clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"53","author":"Tariq","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0004","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e359","article-title":"The prevalence and risk factors of clostridioides difficile infection in inflammatory bowel disease: 10-Year South Korean experience based on the national database","volume":"38","author":"Song","year":"2023","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.dld.2026.10.007_bib0005","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(15)31534-1","article-title":"Su1263 clostridium difficile infection remains an independent risk factor for mortality and colectomy in hospitalized patients with ulcerative colitis","volume":"148","author":"Morrison","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.10.007_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12876-025-03650-3","article-title":"Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era","volume":"25","author":"Mart\u00ednez-Lozano","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-024-03460-z","article-title":"Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: Part 1","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2026.10.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf107","article-title":"ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: Part 2","volume":"19","author":"Yanai","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2026.10.007_bib0010","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.apsb.2025.11.025","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: an evidence-based multidisciplinary guideline","volume":"16","author":"Shi","year":"2026","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dld.2026.10.007_bib0011","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ibd\/izy313","article-title":"A practical guide to the safety and monitoring of new IBD therapies","volume":"25","author":"Click","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.10.007_bib0012","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.10.007_bib0013","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dld.2026.10.007_bib0014","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.dld.2026.10.007_bib0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.10.007_bib0016","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.10.007_bib0017","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.10.007_bib0018","doi-asserted-by":"crossref","first-page":"i1535","DOI":"10.1093\/ecco-jcc\/jjad212.0959","article-title":"P829 Clostridioides difficile infection in patients using vedolizumab and antiTNF: incidence and consequences (CDIFVEDO study of GETECCU)","volume":"18","author":"Gonzalez Vivo","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2026.10.007_bib0019","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/MCG.0000000000001733","article-title":"Risk of gastrointestinal infections after initiating vedolizumab and anti-TNF\u03b1 agents for ulcerative colitis","volume":"57","author":"Dalal","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13099-025-00793-2","article-title":"Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study","volume":"18","author":"Huang","year":"2025","journal-title":"Gut Pathog"},{"key":"10.1016\/j.dld.2026.10.007_bib0021","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/sjg.sjg_118_24","article-title":"Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"30","author":"Alghamdi","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0022","first-page":"31","article-title":"Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: a retrospective cohort study","author":"Saad Alshahrani","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.dld.2026.10.007_bib0023","first-page":"25","article-title":"Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era","author":"Mart\u00ednez-Lozano","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0024","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dld.2026.10.007_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2026.10.007_bib0026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/1751-2980.12994","article-title":"Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)","volume":"22","year":"2021","journal-title":"J Dig Dis"},{"key":"10.1016\/j.dld.2026.10.007_bib0027","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","article-title":"Comparative risk of serious infection with vedolizumab vs anti-tumor necrosis factor in inflammatory bowel disease: results from nationwide swedish registers","volume":"119","author":"Karlqvist","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0028","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor \u03b1 antagonists vs vedolizumab in patients with inflammatory bowel diseases","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.10.007_bib0029","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2026.10.007_bib0030","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. 2005;353:2462\u20132476.","DOI":"10.1056\/NEJMoa050516"},{"key":"10.1016\/j.dld.2026.10.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/17562848261421706","article-title":"Comparative risk of Clostridioides difficile infection in patients with Crohn's disease receiving ustekinumab versus anti-TNF therapy: a retrospective cohort study","volume":"19","author":"Huang","year":"2026","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.dld.2026.10.007_bib0032","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.16742","article-title":"A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn\u2019s disease. The Cross Pennine study II","volume":"55","author":"Lenti","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.10.007_bib0033","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"10.1016\/j.dld.2026.10.007_bib0034","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.dld.2026.10.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2024.392","article-title":"Incubation period of Clostridioides difficile infection in hospitalized patients and long-term care facility residents: a prospective cohort study","volume":"4","author":"Curry","year":"2024","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.dld.2026.10.007_bib0036","first-page":"360","article-title":"Global patterns of clostridioides difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of prevalence","volume":"7","author":"Amakye","year":"2025","journal-title":"Epidemiol Risk Factors, Crohn's Colitis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826009886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826009886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:35:42Z","timestamp":1792524942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826009886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S1590865826009886"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.10.007","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of incident Clostridioides difficile infection with vedolizumab versus anti\u2011TNF in ulcerative colitis: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}